Extract from the Clinical Evaluation Report for Armodafinil

Total Page:16

File Type:pdf, Size:1020Kb

Extract from the Clinical Evaluation Report for Armodafinil AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Armodafinil Proprietary Product Name: Nuvigil Sponsor: Teva Pharmaceuticals Australia Pty Ltd First Round CER report: 4 December 2014 Second Round CER report: 26 April 2015 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report • This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. • The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted. • For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>. Copyright © Commonwealth of Australia 2016 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[email protected]>. Submission PM-2014-01922-1-1 Extract from the Clinical Evaluation Report for Nuvigil 2 / 153 Therapeutic Goods Administration Contents List of abbreviations ________________________________________________________ 5 1. Introduction ___________________________________________________________ 8 1.1. Submission type __________________________________________________________________8 1.2. Drug class and therapeutic indication _________________________________________8 1.3. Dosage forms and strengths ____________________________________________________8 1.4. Dosage and administration______________________________________________________8 2. Clinical rationale ______________________________________________________ 9 3. Contents of the clinical dossier ____________________________________ 10 3.1. Scope of the clinical dossier ___________________________________________________ 10 3.2. Paediatric data __________________________________________________________________ 10 3.3. Good clinical practice __________________________________________________________ 10 4. Pharmacokinetics ____________________________________________________ 11 4.1. Studies providing pharmacokinetic data ____________________________________ 11 4.2. Summary of pharmacokinetics _______________________________________________ 12 4.3. Evaluator's overall conclusions on pharmacokinetics _____________________ 36 5. Pharmacodynamics __________________________________________________ 39 5.1. Study 103 - Healthy young men undergoing acute sleep deprivation ____ 39 5.2. PK/PD modelling and simulations - Report Cephalon CP-05-001 ________ 41 5.3. Evaluator's overall conclusions on pharmacodynamics ___________________ 41 6. Dosage selection for the pivotal studies __________________________ 42 7. Clinical efficacy _______________________________________________________ 42 7.1. Overview of the studies________________________________________________________ 42 7.2. OSAHS ___________________________________________________________________________ 44 7.3. Narcolepsy ______________________________________________________________________ 64 7.4. Shift Work Sleep Disorder (SWSD) ___________________________________________ 74 7.5. Evaluator's conclusions on efficacy ________________________________________ 100 8. Clinical safety _______________________________________________________ 107 8.1. Studies providing evaluable safety data ___________________________________ 107 8.2. Overall extent of exposure __________________________________________________ 108 8.3. Adverse events _______________________________________________________________ 109 8.4. Laboratory tests ______________________________________________________________ 115 8.5. Electrocardiography _________________________________________________________ 118 8.6. Vital signs _____________________________________________________________________ 119 8.7. Polysomnography ____________________________________________________________ 121 Submission PM-2014-01922-1-1 Extract from the Clinical Evaluation Report for Nuvigil 3 / 153 Therapeutic Goods Administration 8.8. Other safety issues ___________________________________________________________ 122 8.9. Post marketing experience __________________________________________________ 123 8.10. Evaluator's overall conclusions on clinical safety _______________________ 124 9. First round benefit-risk assessment ____________________________ 128 9.1. OSAHS _________________________________________________________________________ 128 9.2. Narcolepsy ____________________________________________________________________ 130 9.3. SWSD __________________________________________________________________________ 132 9.4. First round assessment of risks ____________________________________________ 133 9.5. First round assessment of benefit-risk balance ___________________________ 135 10. First round recommendation regarding authorisation ______ 136 11. Clinical questions __________________________________________________ 136 11.1. Pharmacokinetics ___________________________________________________________ 136 11.2. Safety _________________________________________________________________________ 137 12. Second round evaluation of clinical data _______________________ 137 12.1. Pharmacokinetics ___________________________________________________________ 137 12.2. Safety _________________________________________________________________________ 146 13. Second round benefit-risk assessment _________________________ 152 13.1. Second round assessment of benefits ____________________________________ 152 13.2. Second round assessment of risks ________________________________________ 152 13.3. Second round assessment of benefit-risk balance ______________________ 152 14. Second round recommendation regarding authorisation ___ 152 Submission PM-2014-01922-1-1 Extract from the Clinical Evaluation Report for Nuvigil 4 / 153 Therapeutic Goods Administration List of abbreviations Abbreviation Meaning ALT alanine aminotransferase (SGPT) ANC absolute neutrophil count ANCOVA analysis of covariance ANOVA analysis of variance AST aspartate aminotransferase (SGOT) BFI Brief Fatigue Inventory BMI body mass index BP blood pressure bpm beats per minute BUN blood urea nitrogen CDR Cognitive Drug Research (system) CFR Code of Federal Regulations CGI-C Clinical Global Impression of Change CGI-S Clinical Global Impression of Severity of Illness Cmax maximum observed plasma concentration Ctrough plasma trough concentration CMH Cochran-Mantel-Haenzel CRF case report form CRO contract research organization DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition ECG electrocardiography, electrocardiogram ESS Epworth Sleepiness Scale FDA Food and Drug Administration GCP Good Clinical Practice Submission PM-2014-01922-1-1 Extract from the Clinical Evaluation Report for Nuvigil 5 / 153 Therapeutic Goods Administration Abbreviation Meaning GGT gamma-glutamyl transpeptidase HEENT head, eyes, ears, nose, and throat ICH International Conference on Harmonisation ICSD International Classification of Sleep Disorders IEC Independent Ethics Committee IRB Institutional Review Board LLN lower limit of normal range LS least square max maximum MedDRA Medical Dictionary for Regulatory Activities min minimum MSLT Multiple Sleep Latency Test MWT Maintenance of Wakefulness Test OSAHS obstructive sleep apnea/hypopnea syndrome OTC over-the-counter PSG polysomnography RBC red blood cell REM rapid eye movement SD standard deviation SE standard error SOP standard operating procedure SSRI selective serotonin reuptake inhibitor SWSD shift work sleep disorder ULN upper limit of the normal range WBC white blood cell Submission PM-2014-01922-1-1 Extract from the
Recommended publications
  • Modafinil Tablets
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrAURO-MODAFINIL Modafinil Tablets 100 mg House Standard Central Nervous System Stimulant Auro Pharma Inc. 3700 Steeles Avenue West, Suite # 402 Date of Revision: Woodbridge, ON, L4L 8K8, August 8, 2019. CANADA Submission Control Number: 230314 Page 1 of 41 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 4 ADVERSE REACTIONS .............................................................................................. 12 DRUG INTERACTIONS .............................................................................................. 16 DOSAGE AND ADMINISTRATION .......................................................................... 19 OVERDOSAGE ............................................................................................................ 21 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 21 STORAGE AND STABILITY ...................................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use PROVIGIL Safely and Effectively
    PROVIGIL- modafinil tablet Bryant Ranch Prepack ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROVIGIL safely and effectively. See full prescribing information for PROVIGIL. PROVIGIL® (modafinil) tablets, for oral use, C-IV Initial U.S. Approval: 1998 INDICATIONS AND USAGE PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). (1) Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. DOSAGE AND ADMINISTRATION The recommended dosage of PROVIGIL for each indication is as follows: • Narcolepsy or OSA: 200 mg once a day in the morning. (2.1) • SWD: 200 mg once a day, taken approximately one hour prior to start of the work shift. (2.2) • Severe Hepatic Impairment: reduce dose to half the recommended dose. (2.3, 12.3) • Geriatric Patients: consider lower dose. (2.4, 12.3) DOSAGE FORMS AND STRENGTHS Tablets: 100 mg and 200 mg. (3) CONTRAINDICATIONS PROVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. (4) WARNINGS AND PRECAUTIONS • Serious Rash, including Stevens-Johnson Syndrome: Discontinue PROVIGIL at the first sign of rash, unless the rash is clearly not drug-related. (5.1) • Angioedema and Anaphylaxis Reactions: If suspected, discontinue PROVIGIL. (5.2) • Multi-organ Hypersensitivity Reactions: If suspected, discontinue PROVIGIL. (5.3) • Persistent Sleepiness: Assess patients frequently for degree of sleepiness and, if appropriate, advise patients to avoid driving or engaging in any other potentially dangerous activity. (5.4) • Psychiatric Symptoms: Use caution in patients with a history of psychosis, depression, or mania.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Modafinil: a Review of Neurochemical Actions and Effects on Cognition
    Neuropsychopharmacology (2008) 33, 1477–1502 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org Perspective Modafinil: A Review of Neurochemical Actions and Effects on Cognition ,1 1 Michael J Minzenberg* and Cameron S Carter 1Imaging Research Center, Davis School of Medicine, UC-Davis Health System, University of California, Sacramento, CA, USA Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention- deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term ‘modafinil’ and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including working memory and episodic memory, and other processes dependent on prefrontal cortex and cognitive control.
    [Show full text]
  • Methylxanthines and Neurodegenerative Diseases: an Update
    nutrients Review Methylxanthines and Neurodegenerative Diseases: An Update Daniel Janitschke 1,† , Anna A. Lauer 1,†, Cornel M. Bachmann 1, Heike S. Grimm 1, Tobias Hartmann 1,2 and Marcus O. W. Grimm 1,2,* 1 Experimental Neurology, Saarland University, 66421 Homburg/Saar, Germany; [email protected] (D.J.); [email protected] (A.A.L.); [email protected] (C.M.B.); [email protected] (H.S.G.); [email protected] (T.H.) 2 Deutsches Institut für DemenzPrävention (DIDP), Saarland University, 66421 Homburg/Saar, Germany * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Methylxanthines (MTX) are purine derived xanthine derivatives. Whereas naturally occurring methylxanthines like caffeine, theophylline or theobromine are widely consumed in food, several synthetic but also non-synthetic methylxanthines are used as pharmaceuticals, in particular in treating airway constrictions. Besides the well-established bronchoprotective effects, methylxanthines are also known to have anti-inflammatory and anti-oxidative properties, mediate changes in lipid homeostasis and have neuroprotective effects. Known molecular mechanisms include adenosine receptor antagonism, phosphodiesterase inhibition, effects on the cholinergic system, wnt signaling, histone deacetylase activation and gene regulation. By affecting several pathways associated with neurodegenerative diseases via different pleiotropic mechanisms and due to its moderate side effects, intake of methylxanthines have been suggested to be an interesting approach in dealing with neurodegeneration. Especially in the past years, the impact of methylxanthines in neurodegenerative diseases has been extensively studied and several new aspects have been elucidated. In this review Citation: Janitschke, D.; Lauer, A.A.; Bachmann, C.M.; Grimm, H.S.; we summarize the findings of methylxanthines linked to Alzheimer´s disease, Parkinson’s disease Hartmann, T.; Grimm, M.O.W.
    [Show full text]
  • Comparison of Caffeine and D-Amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary
    NIH Public Access Author Manuscript J Addict Res Ther. Author manuscript; available in PMC 2014 November 18. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Addict Res Ther. 2014 ; 5(2): 176–. doi:10.4172/2155-6105.1000176. Comparison of Caffeine and d-amphetamine in Cocaine- Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine Scott D Lane1,*, Charles E Green1, Joy M Schmitz1, Nuvan Rathnayaka1, Wendy B Fang2, Sergi Ferré3, and F Gerard Moeller4 1Center for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center – Houston, Houston, TX USA 2Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA 3Integrative Neurobiology, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA 4Division on Addictions, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA Abstract Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0142957 A1 VAN KEMPEN (43) Pub
    US 2011 O142957A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0142957 A1 VAN KEMPEN (43) Pub. Date: Jun. 16, 2011 (54) METHOD OF TREATING PARTURIENT Publication Classification PLACENTAL MAMMALS IN ORDER TO (51) Int. Cl. REDUCE MATERNAL AND/OR UTERINE A633/42 (2006.01) EXHAUSTION A633/04 (2006.01) A633/00 (2006.01) (76) Inventor: Theo VAN KEMPEN, Sint Stevens A6II 3/522 (2006.01) Woluwe (BE) A63L/35 (2006.01) (21) Appl. No.: 13/030,422 (52) U.S. Cl. ... 424/601; 424/709: 424/722: 514/263.34; 514/654 (22) Filed: Feb. 18, 2011 (57) ABSTRACT Related U.S. Application Data The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of (62) Division of application No. 12/063,830, filed on Aug. reducing delays in the birth process and, thereby, complica 4, 2008, now Pat. No. 7,893,070, filed as application tions resulting there from that may negatively affect the health No. PCT/NL2006/050201 on Aug. 14, 2006. and wellbeing of the mother and increase the incidence of stillbirths and/or neonatal mortality. According to the present (60) Provisional application No. 60/707,954, filed on Aug. invention delays in parturition that result from maternal and/ 15, 2005. or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psycho (30) Foreign Application Priority Data motor stimulants to the parturient mammal prior to and/or during parturition. Said psychomotor stimulant is selected Aug.
    [Show full text]
  • The Transcriptional Repressor Orphan Nuclear Receptor TLX Is Responsive to Caffeine and Istradefylline
    The transcriptional repressor orphan nuclear receptor TLX is responsive to caffeine and istradefylline Giuseppe Faudonea, Whitney Kilua, Xiaomin Nia,b, Apirat Chaikuada,b, Sridhar Sreeramuluc, Pascal Heitela, Harald Schwalbec, Stefan Knappa,b, Manfred Schubert-Zsilavecza, Jan Heeringd, and Daniel Merka* a Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt, Germany b Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Max-von-Laue-Str. 15, D-60438 Frankfurt, Germany c Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Max-von-Laue-Str. 7, D-60438 Frankfurt, Germany d Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, D-60596 Frankfurt, Germany * Correspondence to: [email protected] Abstract. The orphan nuclear receptor TLX is expressed almost exclusively in neural stem cells. TLX acts as an essential factor for neural stem cell survival and is hence considered as a promising drug target in neurodegeneration. However, few studies have characterized the roles of TLX due to a lack of ligands and limited functional understanding. Here, we identify caffeine and istradefylline as TLX ligands that counteract the receptor’s intrinsic repressor activity in reporter gene assays and modulate TLX regulated SIRT1 and p21 expression. Mutagenesis of residues lining a cavity within the TLX ligand binding domain altered activity of these ligands suggesting direct interactions with helix 5. Using istradefylline as a tool compound, we observed ligand-sensitive recruitment of the co-repressor SMRT and heterodimerization of TLX with RXR. Both protein-protein complexes evolve as factors that modulate TLX function and suggest an unprecedented role of TLX in directly repressing other nuclear receptors.
    [Show full text]
  • US 2002/0103350 A1 Lyles (43) Pub
    US 2002O103350A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0103350 A1 Lyles (43) Pub. Date: Aug. 1, 2002 (54) MATERIALS AND METHODS FOR BINDING Publication Classification NUCLECACDS TO SURFACES (51) Int. CI.7. ... C12O 1/68; CO7H 21/04 (76) Inventor: Mark B. Lyles, San Antonio, TX (US) (52) U.S. Cl. ............................................... 536/23.1; 435/6 Correspondence Address: (57) ABSTRACT Baker Botts L.L.P. Surfaces containing high purity Silica (Silicon dioxide) One Shell Plaza exhibit high loading potential for nucleic acids. 901 Louisiana Houston, TX 77002-4995 (US) Formulations containing nucleic acids and materials which mask the electroStatic interactions between the nucleic acids (21) Appl. No.: 09/910,697 and Surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be (22) Filed: Jul. 20, 2001 minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the Surface to proceed. The use of Such formulations additionally minimizes nonspecific Related U.S. Application Data binding of the nucleic acids to the Surface. Examples of materials to be included in Such formulations include cat (60) Provisional application No. 60/220,096, filed on Jul. ions, Xanthines, heXOSes, purines, arginine, lysine, polyargi 21, 2000. nine, polylysine, and quaternary ammonium Salts. US 2002/0103350 A1 Aug. 1, 2002 MATERIALS AND METHODS FOR BINDING DETAILED DESCRIPTION OF THE NUCLEIC ACIDS TO SURFACES INVENTION 0009. The prior art materials and formulations have been FIELD OF THE INVENTION plagued with two general problems; a) low loading potential 0001. The invention relates to silica Surfaces useful for of the Surfaces, and b) nonspecific binding of nucleic acids binding nucleic acids, and formulations to improve the to the Surface.
    [Show full text]
  • PROVIGIL® (Modafinil) Tablets [C-IV] Rx Only
    PI + MG October 2010 PROVIGIL® (modafinil) Tablets [C-IV] Rx Only DESCRIPTION PROVIGIL (modafinil) is a wakefulness-promoting agent for oral administration. Modafinil is a racemic compound. The chemical name for modafinil is 2-[(diphenylmethyl)sulfinyl]acetamide. The molecular formula is C15H15NO2S and the molecular weight is 273.35. The chemical structure is: OO CH S CH2 CNH2 Modafinil is a white to off-white, crystalline powder that is practically insoluble in water and cyclohexane. It is sparingly to slightly soluble in methanol and acetone. PROVIGIL tablets contain 100 mg or 200 mg of modafinil and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, povidone, and magnesium stearate. CLINICAL PHARMACOLOGY Mechanism of Action and Pharmacology The precise mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents like amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of sympathomimetic amines. Modafinil has weak to negligible interactions with receptors for norepinephrine, serotonin, dopamine, GABA, adenosine, histamine-3, melatonin, and benzodiazepines. Modafinil also does not inhibit the activities of MAO-B or phosphodiesterases II-V. 1 PI + MG October 2010 Modafinil-induced wakefulness can be attenuated by the α1-adrenergic receptor antagonist prazosin; however, modafinil is inactive in other in vitro assay systems known to be responsive to α-adrenergic agonists, such as the rat vas deferens preparation. Modafinil is not a direct- or indirect-acting dopamine receptor agonist. However, in vitro, modafinil binds to the dopamine transporter and inhibits dopamine reuptake. This activity has been associated in vivo with increased extracellular dopamine levels in some brain regions of animals.
    [Show full text]
  • Simultaneous Quantification of Antioxidants Paraxanthine
    antioxidants Article Simultaneous Quantification of Antioxidants Paraxanthine and Caffeine in Human Saliva by Electrochemical Sensing for CYP1A2 Phenotyping Rozalia-Maria Anastasiadi 1,*, Federico Berti 2 , Silvia Colomban 3 , Claudio Tavagnacco 2, Luciano Navarini 3 and Marina Resmini 1,* 1 Department of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK 2 Department of Chemical and Pharmaceutical Sciences, University of Trieste, via L. Giorgieri 1, 34127 Trieste, Italy; [email protected] (F.B.); [email protected] (C.T.) 3 Aromalab, illycaffè S.p.A., Area Science Park, Localita’ Padriciano 99, 34149 Trieste, Italy; [email protected] (S.C.); [email protected] (L.N.) * Correspondence: [email protected] (R.-M.A.); [email protected] (M.R.) Abstract: The enzyme CYP1A2 is responsible for the metabolism of numerous antioxidants in the body, including caffeine, which is transformed into paraxanthine, its main primary metabolite. Both molecules are known for their antioxidant and pro-oxidant characteristics, and the paraxanthine- to-caffeine molar ratio is a widely accepted metric for CYP1A2 phenotyping, to optimize dose– response effects in individual patients. We developed a simple, cheap and fast electrochemical based method for the simultaneous quantification of paraxanthine and caffeine in human saliva, by differ- ential pulse voltammetry, using an anodically pretreated glassy carbon electrode. Cyclic voltammetry experiments revealed for the first time that the oxidation of paraxanthine is diffusion controlled with an irreversible peak at ca. +1.24 V (vs. Ag/AgCl) in a 0.1 M H2SO4 solution, and that the mechanism occurs via the transfer of two electrons and two protons.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Paraxanthine Item No. 21068 CAS Registry No.: 611-59-6 Formal Name: 3,7-dihydro-1,7-dimethyl-1H-purine-2,6-dione O Synonyms: 1,7-Dimethylxanthine, NSC 400018 N MF: C7H8N4O2 N FW: 180.2 Purity: ≥98% N N O UV/Vis.: λmax: 269 nm Supplied as: A crystalline solid H Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Paraxanthine is supplied as a crystalline solid. A stock solution may be made by dissolving the paraxanthine in the solvent of choice. Paraxanthine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of paraxanthine in these solvents is approximately 0.5, 30, and 20 mg/ml, respectively. Paraxanthine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, paraxanthine should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Paraxanthine has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Paraxanthine is an inhibitor of phosphodiesterase 9 (PDE9) and an antagonist of adenosine receptors 1,2 A1 and A2 (Kis = 35 and 22 μM, respectively in equine forebrain tissues). It is the main metabolite of caffeine (Item No. 14118) in humans, making up 80% of the three dimethylxanthine metabolites produced by caffeine demethylation.1,3 Paraxanthine increases locomotor activity and counteracts adenosine receptor agonist-induced motor depression in rats not habituated to caffeine.1 At a dose of 30 mg/kg, paraxanthine induces a significant increase in striatal cGMP and extracellular striatal dopamine concentrations in vivo.
    [Show full text]